Author

Lorenzo S Cagnin

Boston Children's HospitalORCID 0009-0007-1980-8340Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:non-human primate· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Francesca Alvarez CalderoniD· 3 shared Leslie S. KeaniD· 3 shared Marlana Winschel· 3 shared Ulrike GerdemanniD· 3 shared Victor TkacheviD· 3 shared Elisa Rojas PalatoiD· 2 shared James KaminskiiD· 2 shared Jennifer F. LaneiD· 2 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Francesca Alvarez CalderonORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologyBlood Immunology & Cellular TherapyPeer-reviewedApr 20, 2026

Precision Editing of Cyclophilin A Generates Cyclosporine and Voclosporin Resistant Cellular Therapies

Holly Wobma, Francesca Alvarez Calderon, Jiayi Dong…·Leslie S. Kean

This study edits Cyclophilin A's C-terminus using CRISPR/Cas9 to create cell therapies resistant to cyclosporine and voclosporin, preserving function in immune suppression settings.

DOI 10.1016/j.bict.2026.100054

mousegenetic perturbation / CRISPR

𝕏 PostBluesky

ImmunologybioRxivPreprintSep 17, 2025

PTPN2-KO CAR-T Cells Demonstrate Enhanced Effector Function, CNS Infiltration, and Toxicity in a Non-Human Primate CAR-T Model

Francesca Alvarez Calderon, Ryan A. Fleming, Marlana Winschel…·Ulrike Gerdemann

DOI 10.1101/2025.09.17.676426

non-human primatebulk RNA-seq

𝕏 PostBluesky

ImmunologyBloodPeer-reviewedApr 1, 2024

B cell directed CAR-T cell therapy results in activation of CD8+ cytotoxic CAR-negative bystander T cells in both non-human primates and patients

James Kaminski, Ryan A. Fleming, Francesca Alvarez Calderon…·Ulrike Gerdemann

The paper identifies a novel mechanism where CAR-T cell therapy activates CD8+ cytotoxic bystander T cells in non-human primates and patients, showing they can kill leukemic cells independently of TCR.

29 citationstop 3%

non-human primatehuman

𝕏 PostBluesky